|
Oct 9
|
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
|
|
Oct 8
|
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
|
|
Sep 25
|
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
|
|
Jul 18
|
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 10
|
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
|
|
Jul 8
|
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 13
|
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
|
|
May 7
|
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
|
|
May 7
|
Ocular Therapeutix™ Reports First Quarter 2024 Results
|
|
May 7
|
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 6
|
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
|
|
May 3
|
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
|
|
May 1
|
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
|
|
Apr 24
|
2 Small-Cap Growth Stocks With Room to Run
|
|
Apr 18
|
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
|
|
Apr 18
|
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
|
|
Apr 16
|
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
|
|
Apr 16
|
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
|
|
Apr 15
|
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
|
|
Apr 9
|
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
|